Fig. 2: Human angiotensin-converting enzyme competition and pseudovirus neutralization responses following SpFN-ALFQ immunization. | npj Vaccines

Fig. 2: Human angiotensin-converting enzyme competition and pseudovirus neutralization responses following SpFN-ALFQ immunization.

From: A SARS-CoV-2 spike ferritin nanoparticle vaccine protects hamsters against Alpha and Beta virus variant challenge

Fig. 2

a Human angiotensin-converting enzyme competition (hACE2) assays were performed from sera taken at week 6, 8, and 11. The vaccine regimens are indicated on the x-axis by PBS (control) or SpFN-ALFQ concentration with the number of vaccinations in the regimen given parenthetically and by color code (blue, 2-dose, red, 1-dose). Inhibitory dose 50% (ID50) are given on the y-axis. b, c Pseudovirus neutralization at weeks 6 and 11 are given against Spike proteins derived from WA1, B.1.1.7, B.1.351 SARS-CoV-2 variants and from SARS-CoV-1. The neutralization titers are given as inhibitory dose 50% (ID50) on the y-axis in logarithmic scale. Box plot bounds depict the standard deviation and the center line the median value. p-values for SpFN-ALFQ vaccination groups compared with PBS control are given just above the boxes in light gray while intra-active regimen p-values are given above the boxes in black. ns not significant (p > 0.05) using the Kruskal–Wallis multiple comparisons test, with Dunn’s correction.

Back to article page